Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Aller, E., Mariman, E
2.5.9.3 Orismilast Orismilast (UNI-50001) is an oral B/D selective PDE-4 inhibitor being studied for moderate to severe UC in the UCORIS trial, a Phase 2a open-label single-arm exploratory study that enrolled adults with UC diagnosed for at least 3 months, MES of 2, on stable 5-ASA or immunomodulator therapy for 3 months, with treatment given twice daily for 12 weeks extendable to 52 weeks (81, 82)
Gastrointestinal side effects and altered dietary patterns could also play a role
M.KayeD
US$ 25.29
US$ 22.03
US$ 29.05
US$ 26.96
US$ 20.63
US$ 22.54
US$ 28.46
US$ 29.96
US$ 29.08
